GPX4: The hub of lipid oxidation, ferroptosis, disease and treatment

  • Biochim Biophys Acta Rev Cancer. 2023 May;1878(3):188890. doi: 10.1016/j.bbcan.2023.188890.
Yi Liu  1 ,  Yicong Wan  2 ,  Yi Jiang  3 ,  Lin Zhang  4 ,  Wenjun Cheng  5
Affiliations
  • 1. Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, Jiangsu 210029, China. Electronic address: [email protected].
  • 2. Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, Jiangsu 210029, China. Electronic address: [email protected].
  • 3. Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, Jiangsu 210029, China. Electronic address: [email protected].
  • 4. Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, Jiangsu 210029, China. Electronic address: [email protected].
  • 5. Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, Jiangsu 210029, China. Electronic address: [email protected].
PMID: 37001616 DOI: 10.1016/j.bbcan.2023.188890
Abstract

Glutathione Peroxidase 4 (GPx4) moonlights as structural protein and antioxidase that powerfully inhibits lipid oxidation. In the past years, it is considered as a key regulator of Ferroptosis, which takes role in the lipid and amine acid metabolism and influences the cell aging, oncogenesis, and cell death. More and more evidences show that targeting GPX4-induced Ferroptosis is a promising strategy for disease therapy, especially Cancer treatment. In view of these, we generalize the function of GPX4 and regulatory mechanism between GPX4 and Ferroptosis, discuss its roles in the disease pathology, and focus on the recent advances of disease therapeutic potential.

Keywords
GPX 4 ferroptosis regulatory disease cancer therapy.